Motor associations of iron accumulation in deep grey matter nuclei in Parkinson's disease: a cross-sectional study of iron-related magnetic resonance imaging susceptibility

European Journal of Neurology

Volumn 24, Issue 2, 2017, Pages 357-365

  Martin Bastida, A ^a   Lao Kaim, N P ^a   Loane, C ^a,b   Politis, M ^a,c   Roussakis, A A ^a   Valle Guzman, N ^d   Kefalopoulou, Z ^e   Paul Visse, G ^f   Widner, H ^g   Xing, Y ^h   Schwarz, S T ^h   Auer, D P ^h   Foltynie, T ^e   Barker, R A ^i,j   Piccini, P ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^f LUND UNIVERSITY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h UNIVERSITY OF NOTTINGHAM   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j MRC COGNITION AND BRAIN SCIENCES UNIT   (United Kingdom)

more..

Author keywords

iron; motor severity; neurodegeneration; Parkinson's disease; SWI

Indexed keywords

IRON;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BRADYKINESIA; BRAIN; BRAIN REGION; CAUDATE NUCLEUS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; PUTAMEN; SEX DIFFERENCE; SUBSTANTIA NIGRA; SUSCEPTIBILITY WEIGHTED IMAGING; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; YOUNG ADULT; AGED; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE PREDISPOSITION; HYPOKINESIA; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY;

ADULT; AGED; CROSS-SECTIONAL STUDIES; DISEASE SUSCEPTIBILITY; FEMALE; GRAY MATTER; HUMANS; HYPOKINESIA; IMAGE PROCESSING, COMPUTER-ASSISTED; IRON; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MOVEMENT DISORDERS; MUSCLE RIGIDITY; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 85006963185     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.13208     Document Type: Article

References (40)

1. Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet 1987; 2: 1219–1220.
2. Hashimoto M, Hsu LJ, Xia Y, et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. NeuroReport 1999; 10: 717–721.
3. Dexter DT, Carayon A, Javoy-Agid F, et al. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 1991; 114(Pt 4): 1953–1975.
4. Haacke EM, Cheng NY, House MJ, et al. Imaging iron stores in the brain using magnetic resonance imaging. Magn Reson Imaging 2005; 23: 1–25.
5. Schenck JF, Zimmerman EA. High-field magnetic resonance imaging of brain iron: birth of a biomarker? NMR Biomed 2004; 17: 433–445.
6. Casey JL, Hentze MW, Koeller DM, et al. Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science 1988; 240: 924–928.
7. Munro HN, Linder MC. Ferritin: structure, biosynthesis, and role in iron metabolism. Physiol Rev 1978; 58: 317–396.
8. Antonini A, Leenders KL, Meier D, Oertel WH, Boesiger P, Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology 1993; 43: 697–700.
9. Ryvlin P, Broussolle E, Piollet H, Viallet F, Khalfallah Y, Chazot G. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol 1995; 52: 583–588.
10. Graham JM, Paley MN, Grunewald RA, Hoggard N, Griffiths PD. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence. Brain 2000; 123(Pt 12): 2423–2431.
11. Kosta P, Argyropoulou MI, Markoula S, Konitsiotis S. MRI evaluation of the basal ganglia size and iron content in patients with Parkinson's disease. J Neurol 2006; 253: 26–32.
12. Martin WR, Wieler M, Gee M. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status. Neurology 2008; 70(16 Pt 2): 1411–1417.
13. Wallis LI, Paley MN, Graham JM, et al. MRI assessment of basal ganglia iron deposition in Parkinson's disease. J Magn Reson Imaging 2008; 28: 1061–1067.
14. Zhang J, Zhang Y, Wang J, et al. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study. Brain Res 2010; 1330: 124–130.
15. Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiple system atrophy with predominant parkinsonism and idiopathetic Parkinson diseases demonstrated by phase-corrected susceptibility-weighted imaging. AJNR Am J Neuroradiol 2012; 33: 266–273.
16. Jin L, Wang J, Jin H, et al. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease. Eur J Neurol 2012; 19: 969–976.
17. Bunzeck N, Singh-Curry V, Eckart C, et al. Motor phenotype and magnetic resonance measures of basal ganglia iron levels in Parkinson's disease. Parkinsonism Relat Disord 2013; 19: 1136–1142.
18. Wu SF, Zhu ZF, Kong Y, et al. Assessment of cerebral iron content in patients with Parkinson's disease by the susceptibility-weighted MRI. Eur Rev Med Pharmacol Sci 2014; 18: 2605–2608.
19. Hopp K, Popescu BF, McCrea RP, et al. Brain iron detected by SWI high pass filtered phase calibrated with synchrotron X-ray fluorescence. J Magn Reson Imaging 2010; 31: 1346–1354.
20. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55: 181–184.
21. Haacke EM, Miao Y, Liu M, et al. Correlation of putative iron content as represented by changes in R2* and phase with age in deep gray matter of healthy adults. J Magn Reson Imaging 2010; 32: 561–576.
22. Hallgren B, Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem 1958; 3: 41–51.
23. Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol 2001; 54: 414–418.
24. Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One 2013; 8: e57904.
25. Wieler M, Gee M, Martin WR. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI. Parkinsonism Relat Disord 2015; 21: 179–183.
26. Pfefferbaum A, Adalsteinsson E, Rohlfing T, Sullivan EV. MRI estimates of brain iron concentration in normal aging: comparison of field-dependent (FDRI) and phase (SWI) methods. NeuroImage 2009; 47: 493–500.
27. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58–64.
28. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013; 80: 1850–1855.
29. Dexter DT, Statton SA, Whitmore C, et al. Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration. J Neural Transm (Vienna) 2011; 118: 223–231.
30. Devos D, Moreau C, Devedjian JC, et al. Targeting chelatable iron as a therapeutic modality in Parkinson's disease. Antioxid Redox Signal 2014; 21: 195–210.
31. Haacke EM, Xu Y, Cheng YC, Reichenbach JR. Susceptibility weighted imaging (SWI). Magn Reson Med 2004; 52: 612–618.
32. Haacke EM, Ayaz M, Khan A, et al. Establishing a baseline phase behavior in magnetic resonance imaging to determine normal vs. abnormal iron content in the brain. J Magn Reson Imaging 2007; 26: 256–264.
33. Haacke EM, Mittal S, Wu Z, Neelavalli J, Cheng YC. Susceptibility-weighted imaging: technical aspects and clinical applications, part 1. AJNR Am J Neuroradiol 2009; 30: 19–30.
34. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry. Brain 1999; 122(Pt 8): 1421–1436.
35. Sasaki M, Shibata E, Tohyama K, et al. Monoamine neurons in the human brain stem: anatomy, magnetic resonance imaging findings, and clinical implications. NeuroReport 2008; 19: 1649–1654.
36. Oikawa H, Sasaki M, Tamakawa Y, Ehara S, Tohyama K. The substantia nigra in Parkinson disease: proton density-weighted spin-echo and fast short inversion time inversion-recovery MR findings. AJNR Am J Neuroradiol 2002; 23: 1747–1756.
37. Sasaki M, Shibata E, Tohyama K, et al. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. NeuroReport 2006; 17: 1215–1218.
38. Schwarz ST, Rittman T, Gontu V, Morgan PS, Bajaj N, Auer DP. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Mov Disord 2011; 26: 1633–1638.
39. Langley J, Huddleston DE, Chen X, Sedlacik J, Zachariah N, Hu X. A multicontrast approach for comprehensive imaging of substantia nigra. NeuroImage 2015; 112: 7–13.
40. Barbosa JH, Santos AC, Tumas V, et al. Quantifying brain iron deposition in patients with Parkinson's disease using quantitative susceptibility mapping, R2 and R2. Magn Reson Imaging 2015; 33: 559–565.